New combo therapy targets Hard-to-Treat liver and stomach cancers
NCT ID NCT03259867
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a two-step treatment for people with advanced liver cancer (hepatocellular carcinoma) or metastatic stomach cancer that has worsened despite prior immunotherapy. First, doctors deliver a drug called tirapazamine directly into the liver tumor through a procedure called TATE (transarterial embolization). Then, patients receive the immunotherapy drug nivolumab (Opdivo) to boost the immune system. The goal is to see if this combination can shrink tumors or slow disease progression. About 54 adults aged 18 to 80 will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirapazamine embolization plus nivolumab
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced liver or gastric cancer who have stopped responding to immunotherapy.
What could go wrong
This is an early phase 2 trial with only 54 participants, so results may not apply to everyone. The treatment involves a procedure and a drug, which may cause side effects or not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
-
University of California, Irvine
RECRUITINGOrange, California, 92868, United States
Contact Email: •••••@•••••
Contact
Contact
-
University of Oklahoma Health Science Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Email: •••••@•••••